Espinoza, Manuel Antonio http://orcid.org/0000-0001-9564-9512
Rojas, Rubén
Zaupa, Alessandro
Balmaceda, Carlos http://orcid.org/0000-0002-8381-2439
Funding for this research was provided by:
Merck S.A.
Article History
Accepted: 9 June 2021
First Online: 5 July 2021
Declarations
:
: This study was funded by Merck S.A., Chile (a business of Merck KGaA, Darmstadt, Germany), commissioned to Pontificia Universidad Católica (Santiago, Chile) under strict independence agreement.
: Investigators have realized this study in the context of their salary condition paid by the university and no further incentives were provided for this study. All authors declare they have received compensation from diverse pharmaceutical companies for educational services. CB has received honorarium from different pharmaceutical companies for educational services. ME has received compensation from diverse pharmaceutical companies for training on economic evaluation and prioritization in healthcare. RR has received compensation from diverse pharmaceutical companies for educational services and as a consultant.
: The authors confirm that the data supporting the findings of this study are available within the article.
: The economic model used in this study is not publicly available by request of the local company. Any request can be coordinated by the corresponding author on reasonable request.
: All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by CB, MAE, RR, and AZ. The first draft of the manuscript was written by MAE and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.